Selective dependence on OXPHOS, associated to low glycolytic capacity indicates BCL-2 inhibitors (VTX) plus AZA, the standard of care for patients with newly diagnosed AML unfitted for intensive chemotherapy [39], as a therapy for resistant and relapsed APL patients. Here, BCL2 is linked to acute promyelocytic leukemia.